Summary of Chikungunya: vacina com 98% de eficácia contra o vírus pode chegar ao Brasil em 2024

00:00:00 - 00:00:00

In the near future, Brazil may see a vaccine for chikungunya that is 98% effective in protecting against the virus. The vaccine was developed by a European laboratory in collaboration with the Instituto Butantan and has already shown high efficacy in clinical trials. The chikungunya virus causes symptoms such as fever, red rashes, and severe body pain, and can lead to long-term complications. Currently, there is no specific treatment for chikungunha, and the current preventive methods have been ineffective. Although the vaccine has been approved in the US, it is still awaiting authorization in Brazil by Anvisa in order to be distributed for free through the SUS system.

• 00:00:00 In this section, it is discussed how a vaccine against chikungunya, which has an efficacy rate of 98%, may soon be available in Brazil. The vaccine was developed by a European laboratory in partnership with the Instituto Butantan and has already shown high efficacy in clinical trials. The chikungunya virus causes symptoms of fever, red rashes, and severe body pain, and can lead to long-term complications such as neurological, renal, and cardiac problems. Currently, there is no specific treatment for chikungunha, and the current preventive methods have been ineffective. Although the vaccine has been approved in the US, it is still awaiting authorization in Brazil by Anvisa so that it can be distributed for free through the SUS system.